Conference
Neoadjuvant temsirolimus in high-risk renal cell carcinoma: Results from a single-center prospective study.
Abstract
387
Background: The current first-line treatment for advanced renal cell carcinoma (RCC) includes targeted therapy with or without cytoreductive radical nephrectomy. There is a paucity of data as to the effectiveness of adjuvant and neoadjuvant treatment before radical nephrectomy for localized high-risk or advanced disease. We initiated a trial of neoadjuvant Temsirolimus before radical nephrectomy for locally advanced and …
Authors
Sheikh AA; Gharajeh A; Hotte SJ; Pinthus JH; Kapoor A
Volume
29
Pagination
pp. 387-387
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2011
DOI
10.1200/jco.2011.29.7_suppl.387
Conference proceedings
Journal of Clinical Oncology
Issue
7_suppl
ISSN
0732-183X